10LBA Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non smal... von Soria, J, Sequist, L.V, Goldman, J.W, Wakelee, H.A, Gadgeel, S.M, Varga, A, Yu, H.A, Solomon, B.J, Ou, S.H, Papadimitrakopoulou, V, Oxnard, G.R, Horn, L, Dziadziuszko, R, Chao, B, Spira, A.I, Liu, S, Mekhail, T, Matheny, S, Litten, J, Camidge, R.D

Volltext

1011P FORTITUDE phase I study of NG-350A, a novel tumour-selective adenoviral vector expressing an anti-CD40 agonist antibody: Monotherapy dose escalation results von Naing, A., Rosen, L., Camidge, R.D., Khalil, D., Davies, J., Miles, D., Patel, M., Cockle, P., Champion, B., Krige, D., Lillie, T.

Volltext

444PD - Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study) von Drilon, A., Cho, B.C., Kim, D.-W., Lee, J., Lin, J.J., Zhu, V., Camidge, R.D., Stopatschinskaja, S., Cui, J.J., Hyman, D.M., Ou, S.-H., Shaw, A.T., Doebele, R.C.

Volltext

Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC von Mok, T.S.K., Shaw, A.T., Camidge, R.D., Gadgeel, S.M., Rosell, R., Dziadziuszko, R., Kim, D.-W., Perol, M., Ou, S.-H., Bordogna, W., Smoljanović, V., Hilton, M., Peters, S.

Volltext

1484PD - Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC von Mok, T.S.K., Shaw, A.T., Camidge, R.D., Gadgeel, S.M., Rosell, R., Dziadziuszko, R., Kim, D.-W., Perol, M., Ou, S.-H., Bordogna, W., Smoljanović, V., Hilton, M., Peters, S.

Volltext

Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study) von Drilon, A., Cho, B.C., Kim, D.-W., Lee, J., Lin, J.J., Zhu, V., Camidge, R.D., Stopatschinskaja, S., Cui, J.J., Hyman, D.M., Ou, S.-H., Shaw, A.T., Doebele, R.C.

Volltext

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry von Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A.B., Mezquita, L., Thai, A.A., Mascaux, C., Couraud, S., Veillon, R., Van den Heuvel, M., Neal, J., Peled, N., Früh, M., Ng, T.L., Gounant, V., Popat, S., Diebold, J., Sabari, J., Zhu, V.W., Rothschild, S.I., Bironzo, P., Martinez-Marti, A., Curioni-Fontecedro, A., Rosell, R., Lattuca-Truc, M., Wiesweg, M., Besse, B., Solomon, B., Barlesi, F., Schouten, R.D., Wakelee, H., Camidge, D.R., Zalcman, G., Novello, S., Ou, S.I., Milia, J., Gautschi, O.

Volltext

A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) Combined with Erlotinib for Patients with Recurrent Non-small Cell Lung Cancer (NSCLC) von Kavanagh, B, Abdulrahman, R, Camidge, D.R, Gerber, D.E, Bunn, P.A, Schiller, J, Choy, H, Gaspar, L, Doebele, R, Timmerman, R.D

Volltext